Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Immunome, Inc.

< Previous 1 2 Next >
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Appoints Phil Tsai as Chief Technical Officer
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Announces Completion of Purchase of Assets from Atreca
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome to Present at 2024 Bank of America Healthcare Conference
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Appoints Kinney Horn as Chief Business Officer
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome to Participate in the Leerink Partners Global Biopharma Conference
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Announces Pricing of Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome Announces Proposed Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
Tickers IMNM
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
From Immunome, Inc.
Via Business Wire
Tickers ADXS IMNM
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Immunome, Inc.
Via Business Wire
Tickers IMNM
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.